AngioDynamics, Inc. (ANGO) |
| 11.44 -0.02 (-0.17%) 02-27 16:00 |
| Open: | 11.43 |
| High: | 11.48 |
| Low: | 11.3 |
| Volume: | 193,728 |
| Market Cap: | 472(M) |
| PE Ratio: | -17.07 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 13.76 |
| Resistance 1: | 11.78 |
| Pivot price: | 11.16 |
| Support 1: | 10.52 |
| Support 2: | 9.74 |
| 52w High: | 13.99 |
| 52w Low: | 8.27 |
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
| EPS | -0.670 |
| Book Value | 4.240 |
| PEG Ratio | 0.00 |
| Gross Profit | 4.069 |
| Profit Margin (%) | -9.02 |
| Operating Margin (%) | -3.14 |
| Return on Assets (ttm) | -4.6 |
| Return on Equity (ttm) | -15.3 |
Fri, 27 Feb 2026
AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 68.70% Potential Upside Amid Healthcare Innovations - DirectorsTalk Interviews
Mon, 23 Feb 2026
Hear AngioDynamics CEO Jim Clemmer live at Leerink healthcare conference - Stock Titan
Fri, 20 Feb 2026
AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 72.62% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Mon, 16 Feb 2026
Bastion Asset Management Inc. Buys 304,960 Shares of AngioDynamics, Inc. $ANGO - MarketBeat
Tue, 10 Feb 2026
Essex Investment Management Co. LLC Increases Holdings in AngioDynamics, Inc. $ANGO - MarketBeat
Fri, 06 Feb 2026
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect? - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |